Clinical trials of the first anti-aging therapy
We are pleased to announce that UNITY Biotechnology has begun clinical trials on a human first real rejuvenating therapy, which directly targets one of the causes of aging: the cells of the senescent.
senolitic drugs , was announced back in June, and most of the world has not paid much attention to it, and that its success may represent a future medicine. We're talking about UNITY Biotechnology about the beginning of tests of its senolitic preparation UBX0101 in patients suffering from osteoarthritis.
The senolitic educational program
SENOLITHICS are a class of drugs that can potentially affect the sensor cells that are one of the causes of aging . Simply put, the cell becomes sentenced when it loses the ability to share. This happens as a response to DNA damage, and therefore it is a kind of protection in order to prevent the multiplication of cells containing mutations, for example, such as cancerous cells. This response can be caused by the exhaustion of telomeres, since the cell performs the maximum number of divisions it is capable of, or other external stresses, such as oxidative stress.
Cellular aging helps prevent cancer and is important in wound healing; However, the accumulation of cells in the sense of time is harmful. Sensory cells emit a cocktail of chemicals known as associated with aging secretory phenotype (SASP), which is associated with a number of age-related diseases; SASP promotes tissue inflammation and causes aging in neighboring healthy cells, triggering a kind of chain reaction.
While sensory cells are usually destroyed by the immune system, a growing number are avoiding destruction due to immune aging-the age-related decline in the ability of the immune system to do its job. This, in turn, leads to the accumulation of senescent cells and an increase in chronic inflammation.
For several years, it was suggested that the selective elimination of the sensory cells can reduce, potentially stop and reverse some age-related pathologies; several bioengineering companies have developed various kinds of cenoliths aimed at the sensor cells, leaving healthy cells intact. The results on mice of different ages were very good, but the only way to find out whether a cenolitic would be useful to a person is to run a clinical trial on a person.
UNITY Biotechnology and test UBX0101
UNITY Biotechnology was founded in 2011 by Jan van Dursen, Judith Campizi, Nathaniel David and Daohun Zhou. UNITY focuses on the destruction of cell-based cells, but the company is also working on mitochondrial dysfunction and the loss of circulating youthful factors. Its plans include several drugs that are currently in the optimization phase, and the UBX0101 has just entered phase 1 of a randomized, double-blind, placebo-controlled, FDA-approved clinical trial .
UBX0101 is currently being tested for safety in patients suffering from mild and severe osteoarthritis associated with the age of autology that affects joints and causes destruction of cartilage and bone. This pathology can cause joint edema, decreased mobility, joint pain and stiffness affecting everyday life. Cellular aging is associated with osteoarthritis, and affects different joints, but now the UNITY study focuses on knee osteoarthritis. Although this test is intended primarily to assess the safety and tolerability of a single injection, efficacy will also be monitored.
It's too early to say how well the cenolithics will work in public, but regardless of this, the process can be considered an important milestone on the road to a world free from aging. Despite the fact that this study is focused on a certain pathology, the UNITY approach is aimed at the primary cause of aging, reversal of the disease or at least slowing it down; Currently, osteoarthritis is treated - like most age-related pathologies - only symptomatically.
If the test is successful, it will attract more resources for such studies with a view to further improving the approach and possibly extending it to other pathologies; other companies can follow the example of UNITY and join the race in order to improve the technology, which has already proved its effectiveness; more generally, a successful senolitic test will provide proof of the concept that human aging is amenable to medical intervention not only in theory but also in practice. This can be a fatal blow struck by a pro-trading trance, which causes many people to believe that there is no need to interfere with aging.
UNITY also has a second candidate for senolithics, UBX196? an inhibitor of specific members of the family of regulatory proteins of apoptosis BCL-? which is scheduled for Phase 1 clinical trials in the treatment of ocular diseases in the second half of 2019.
This is the first real rejuvenating therapy in clinical trials in humans, based on the repair approach to aging, back in 2004 developed by Aubrey de Gray from SENS. The removal of these problem cells has long been suggested as a way to combat age-related pathologies and we have reached a point where more than a decade of research is finally ready for testing.
If the test fails, it will soon provide us with invaluable information, deepen our understanding of aging and allow us to try again. In any case, it will be a win-win option. We are happy to update our Rejuvenation Card , including in it UNITY, and we wish them success!